Thymosin Beta-4

Also known as: Tβ4, Timbetasin

Thymosin Beta-4 (Tβ4) is a 43-amino acid actin-sequestering peptide that regulates cytoskeletal dynamics by binding monomeric G-actin, thereby inhibiting actin polymerization and promoting cell motility. Its mechanism of action extends beyond actin binding to include upregulation of matrix metalloproteinases, activation of integrin-linked kinase (ILK), and induction of vascular endothelial growth factor (VEGF), collectively driving angiogenesis, wound healing, and tissue repair. These effects are particularly pronounced in cardiac, corneal, and dermal tissues, where Tβ4 reduces inflammation, fibrosis, and apoptosis while enhancing cell migration and regeneration. Key research findings from clinical trials demonstrate Tβ4’s efficacy in accelerating corneal epithelial wound healing and reducing scar formation in ocular injuries. In cardiac models, Tβ4 improves myocardial repair post-ischemia by promoting neovascularization and cardiomyocyte survival. Dermal studies show enhanced wound closure and reduced scarring, with phase II trials indicating safety and tolerability in chronic wounds. Preclinical data also suggest neuroprotective and anti-inflammatory properties, though these require further validation. Clinically, Tβ4 is under investigation for acute myocardial infarction, corneal defects, and pressure ulcers, with potential applications in stroke and neurodegenerative diseases. Its ability to modulate actin dynamics and regenerative pathways positions it as a candidate for tissue repair and fibrosis reduction. However, large-scale phase III trials are needed to confirm efficacy and establish standardized dosing. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides